DR. BRATATEE ROY

DR. NEETI AGRAWAL, DR. SONICA DEVI HENAM, Dr.Mondal Lakshmi Kanta

Abstract

RCT trials of anti-VEGF therapy reveal that around 35-45% of DME patients are non responsive to anti-VEGF agents. AIM :To determine the biochemical factors of anomalous glucose metabolism and advanced lipoxidation end products in lipid -rich environment of retina, which affect anti-VEGF treatment outcomes in DME. METHODS: 200 DME patients underwent intravitreal administration of Ranibizumab at monthly intervals for 3 months, followed by laser therapy as required. 77 patients who did not respond to this therapy were assessed for lactate dehydrogenase (LDH) and advanced lipoxidation end products (ALEs) levels in their serum. LDH activity was measured by polarographic measurement of NAD+ formed. ALEs levels were measured by ELISA probe. RESULTS :Non- responders demonstrated 2-3 times higher serum levels of LDH and ALEs in comparison to the responder group. CONCLUSION: Higher levels of circulating LDH and ALEs impair the action of anti-VEGF molecules in DME.

Full Text